Suncrest_GA45977 - evaluate the efficacy of RO7837195 compared with placebo in inducing remission

  • Research type

    Research Study

  • Full title

    A PHASE IIb, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED INDUCTION STUDY WITH AN ACTIVE TREATMENT EXTENSION TO ASSESS THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF RO7837195 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

  • IRAS ID

    1012418

  • Contact name

    Tracy Ogbunamiri

  • Contact email

    ogbunamiri.tracy@gene.com

  • Sponsor organisation

    Genentech, Inc.

  • Clinicaltrials.gov Identifier

    NCT06979336

  • Research summary

    The purpose of this study is to compare the effects, good or bad, of different doses of RO7837195 versus placebo on patients with ulcerative colitis. This study has three parts: 1. Screening 2. Treatment 3. Follow-up
    Over the treatment period, patients will receive either RO7837195 or placebo, as indicated below:
    • RO7837195, given on Day 1 as an infusion (into the vein) over about 1 hour, then as an injection once a month (starting at Week 4) for 12 months
    • Placebo, given on Day 1 as an infusion over about 1 hour, then as an injection once a month (starting at Week 4) for 2 months.
    Thereafter, placebo will switch to RO7837195, given as an injection once a month for 10 months. A placebo looks like a drug but has no active ingredient.
    During this study, patients will have visits approximately every 4 weeks while they are receiving treatment. Patients will also have two follow-up visits at 4 weeks and 17 weeks after final dose of study treatment. Visits may last 2-6 hours. Total time in the study for patients will be about 16 months. About 224 people will take part in this study.
    Genentech, Inc. (a member of the Roche Group) is the sponsor of this study.

  • REC name

    West Midlands - Edgbaston Research Ethics Committee

  • REC reference

    25/WM/0143

  • Date of REC Opinion

    19 Aug 2025

  • REC opinion

    Further Information Favourable Opinion